We are live on
!
Find out more
PFM
Privium Fund Management Portfolio holdings
AUM
$544M
1-Year Est. Return
72.49%
This Fund
S&P 500
This Quarter
Est. Return
-13.18%
1 Year Est. Return
+72.49%
3 Year Est. Return
+451.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$480M
AUM Growth
-$62.8M
(-12%)
Cap. Flow
+$19.4M
Cap. Flow
% of AUM
4.03%
Top 10 Holdings %
Top 10 Hldgs %
63.98%
Holding
64
New
7
Increased
24
Reduced
17
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESPR
Esperion Therapeutics
ESPR
|
+$10.4M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$5.38M |
| 3 |
Denali Therapeutics
DNLI
|
+$5.07M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$4.16M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$3.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$5.47M |
| 2 |
Merck
MRK
|
+$3.85M |
| 3 |
Tesla
TSLA
|
+$2.68M |
| 4 |
Arrowhead Research
ARWR
|
+$1.98M |
| 5 |
VZLA
Vizsla Silver
VZLA
|
+$1.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.85% |
| 2 | Consumer Discretionary | 24.98% |
| 3 | Technology | 24.21% |
| 4 | Financials | 8.49% |
| 5 | Communication Services | 6.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SA
51
Seabridge Gold
SA
$3.62B
| $704K | 0.15% |
24,828
+1,072
| +5% | +$34.2K |
|
52
SandRidge Energy
SD
$519M
| $633K | 0.13% |
38,792
| – | – |
|
|
AUTL
53
Autolus Therapeutics
AUTL
$548M
| $502K | 0.1% |
363,430
+37,185
| +11% | +$56.5K |
|
54
Fate Therapeutics
FATE
$298M
| $497K | 0.1% |
414,311
+45,211
| +12% | +$55K |
|
55
Voyager Therapeutics
VYGR
$197M
| $463K | 0.1% |
120,000
+25,000
| +26% | +$98.4K |
|
56
Tidewater
TDW
$4.65B
| $458K | 0.1% |
5,483
| – | – |
|
57
B2Gold
BTG
$6.82B
| $437K | 0.09% |
+96,477
| New | +$484K |
|
58
Noble Corp
NE
$7.23B
| $336K | 0.07% |
6,849
-4,000
| -37% | -$163K |
|
59
Pan American Silver
PAAS
$20.1B
| $213K | 0.04% |
+3,900
| New | +$225K |
|
60
Sprott Uranium Miners ETF
URNM
$2.01B
| $209K | 0.04% |
3,302
-2,105
| -39% | -$144K |
|
|
61
Merck
MRK
$331B
| – | – |
-36,593
| Closed | -$3.85M |
|
62
Nomad Foods
NOMD
$1.65B
| – | – |
-8,199
| Closed | -$103K |
|
63
Valaris
VAL
$6.09B
| – | – |
-6,315
| Closed | -$318K |
|
|
VZLA
64
Vizsla Silver
VZLA
$1.34B
| – | – |
-204,654
| Closed | -$1.12M |
|
Similar funds
BCM
AA
HIS
FMC
WCP
CM
LSCM
KI
Privium Fund Management's Q1 2026 Portfolio in Review
As of Q1 2026, Privium Fund Management held 64 positions worth $480M, down 12% from $543M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Privium Fund Management deployed $19.4M of net new capital in Q1 2026, opening 7 new positions and adding to 24 existing holdings. Its largest new stake was Esperion Therapeutics: 3,299,441 shares worth $9.04M.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 29% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Biogen, an estimated $5.47M trimmed.
- Privium Fund Management's largest Q1 2026 buy was Esperion Therapeutics: 3,299,441 shares worth $9.04M.
- Privium Fund Management added most to Ionis Pharmaceuticals in Q1 2026, an estimated $3.88M increase.
- Privium Fund Management's biggest Q1 2026 reduction was Biogen, cutting an estimated $5.47M.
- Privium Fund Management fully exited Merck in Q1 2026, selling an estimated $3.85M.
- Privium Fund Management's ten largest holdings make up 64% of its $480M portfolio in Q1 2026.
- Privium Fund Management opened 7 new positions and closed 4 in Q1 2026.
- Privium Fund Management's portfolio value fell 12% quarter-over-quarter to $480M.
Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.